Want to see IN:MANGALAM full AI Analyst Report?
Top Page
Mangalam Drugs & Organics Ltd.
(MANGALAM)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹33.00
▲(8.55% Upside)
Action:Reiterated
Date:09/16/26
Overall score is held back primarily by weak financial performance (FY2026 losses, negative operating/free cash flow, and higher leverage). This is partially offset by constructive price momentum (above key moving averages and positive MACD), while valuation remains challenged due to negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Specialty chemical intermediate platform
A focused portfolio of specialty intermediates gives Mangalam an established industrial role across pharmaceutical and chemical value chains. Serving both domestic and export customers broadens the addressable market and allows growth through volumes, product mix, and downstream derivatives.
Negative Factors
Sharp profitability deterioration
The move from modest profit to substantial net and operating losses weakens internal funding capacity and makes earnings less predictable. Persistent negative operating margins would reduce the resources available for maintenance, investment, debt service, and rebuilding customer or market momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty chemical intermediate platform
A focused portfolio of specialty intermediates gives Mangalam an established industrial role across pharmaceutical and chemical value chains. Serving both domestic and export customers broadens the addressable market and allows growth through volumes, product mix, and downstream derivatives.
Read all positive factors
Mangalam Drugs & Organics Ltd. (MANGALAM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹472.16M
Dividend Yield0.28%
Average Volume (3M)12.40K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth-22.27%
EPS Growth-291.72%
CountryIN
Employees319
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-24.16
Shares Outstanding15,828,248
10 Day Avg. Volume10,434
30 Day Avg. Volume12,400
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model
Company Description
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated phar...
How the Company Makes Money
Mangalam Drugs & Organics Ltd. primarily makes money by manufacturing and selling specialty chemical intermediates (including products such as allyl chloride and its derivatives) to business customers. Revenue is generated from (1) domestic sales ...
Mangalam Drugs & Organics Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
42
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.32B | 2.32B | 3.18B | 3.67B | 3.70B | 4.47B |
| Gross Profit | 286.30M | 232.46M | 1.50B | 188.12M | 287.77M | 546.89M |
| EBITDA | -87.59M | -149.03M | 363.25M | 174.95M | 259.54M | 451.84M |
| Net Income | -382.41M | -444.00M | 67.21M | -90.72M | 12.70M | 196.57M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.15B | 3.66B | 3.34B | 3.60B | 3.28B |
| Cash, Cash Equivalents and Short-Term Investments | 7.51M | 7.01M | 25.89M | 11.87M | 26.88M | 19.55M |
| Total Debt | 0.00 | 1.05B | 962.30M | 1.07B | 885.47M | 879.04M |
| Total Liabilities | -1.03B | 2.12B | 2.17B | 1.98B | 2.08B | 1.78B |
| Stockholders Equity | 1.03B | 1.03B | 1.49B | 1.36B | 1.52B | 1.51B |
Cash Flow | ||||||
| Free Cash Flow | 19.14M | -208.11M | 223.93M | -79.20M | 116.09M | -19.60M |
| Operating Cash Flow | 77.10M | -89.12M | 425.94M | 39.13M | 395.23M | 257.09M |
| Investing Cash Flow | -57.59M | -117.25M | -194.72M | -118.27M | -221.72M | -273.26M |
| Financing Cash Flow | -11.63M | 187.49M | -217.12M | 52.27M | -166.17M | 29.79M |
Mangalam Drugs & Organics Ltd. Technical Analysis
Positive
30.40
Price Trends
29.90
Positive
29.30
Positive
30.68
Positive
Market Momentum
0.07
Positive
52.18
Neutral
30.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Positive. The current price of 30.4 is below the 20-day moving average (MA) of 31.91, above the 50-day MA of 29.90, and below the 200-day MA of 30.68, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 52.18 is Neutral, neither overbought nor oversold. The STOCH value of 30.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MANGALAM.
Mangalam Drugs & Organics Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.55B | 10.42 | ― | 0.70% | 4.29% | 2.40% | |
62 Neutral | ₹887.55M | 23.96 | ― | ― | 3.08% | 972.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹472.16M | -1.32 | ― | 0.28% | -22.27% | -291.72% | |
47 Neutral | ₹481.22M | 101.83 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹488.36M | -0.30 | ― | 0.67% | -39.80% | -452.04% | |
42 Neutral | ₹270.05M | -1.61 | ― | 0.67% | -95.17% | 50.07% |
* General Sector Average
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
31.67
-37.11
-53.95%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
30.38
-9.88
-24.54%
IN:LASA
Lasa Supergenerics Ltd.
5.39
-6.12
-53.17%
IN:PAR
Par Drugs and Chemicals Limited
122.74
18.59
17.85%
IN:VAISHALI
Vaishali Pharma Ltd.
8.17
-2.92
-26.33%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.18
1.28
26.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.